Search Within

David H Ilson

Formats
  1. Journal Article (210)
  2. Meeting Abstract (169)
  3. Book Section (20)
  4. Review (14)
  5. Editorial (9)
  6. Conference Paper (6)
  7. Guidelines (3)
  8. Correspondence (2)
  9. Book Whole (1)
  10. Miscellaneous (1)
  11. Research Letter (1)
Groups
  1. Department of Medicine (436)
  2. Gastrointestinal Oncology Service (436)
  3. Solid Tumor Oncology Division (436)
  4. Center for Pancreatic Cancer Research (187)
  5. Surgery (137)
  6. Survivorship Research (127)

More Groups

People
  1. David Kelsen (132)
  2. Geoffrey Ku (123)
  3. Yelena Janjigian (112)
  4. Marinela Capanu (65)
  5. Laura Tang (60)
  6. Manjit Bains (51)

More People

Years
  1. 2025 (8)
  2. 2024 (16)
  3. 2023 (24)
  4. 2022 (21)
  5. 2021 (22)
  6. 2020 (20)

More Years

Publications
  1. Journal of Clinical Oncology (135)
  2. Annals of Oncology (28)
  3. International Journal of Radiation Oncology, Biology, Physics (15)
  4. Journal of the National Comprehensive Cancer Network (14)
  5. Annals of Surgical Oncology (13)
  6. Cancer (12)

More Publications

Publishers
  1. American Society of Clinical Oncology (137)
  2. Elsevier Inc. (59)
  3. Oxford University Press (41)
  4. Springer (32)
  5. Lippincott Williams & Wilkins (22)
  6. Wiley Blackwell (19)

More Publishers

Results (436)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Long-term outcomes in patients with gastric cancer after conversion from positive to negative peritoneal cytology
    Meeting Abstract

    Ellis, R. J.; Dikken, J. L.; Schlick, C. J. R.; Jadeja, B.; Ilson, D. H.; Ku, G. Y.; Tang, L. H.; Brennan, M. F.; Strong, V. E.; Coit, D. G.
    Annals of Surgical Oncology (2024)

    Fulltext@MSK | Save
  • How to use anti-PD-1 therapy in gastric cancer: The approach in the United States
    Review

    Ilson, D. H.
    Chinese Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Clinical and molecular characteristics of early-onset vs average-onset esophagogastric cancer
    Journal Article

    Lumish, M. A.; Walch, H.; Maron, S. B.; Chatila, W.; Kemel, Y.; Maio, A.; Ku, G. Y.; Ilson, D. H.; Won, E.; Li, J.; more...
    JNCI: Journal of the National Cancer Institute (2024)

    Fulltext@MSK | Save
  • Metastatic esophagogastric cancer
    Book Section

    Ku, G. Y.; Ilson, D. H.
    In Abutalib, S. A.; Markman, M.; Benson, A. B. 3rd; Rugo, H. S. (Eds.) Cancer Consult: Expertise in Clinical Practice. 2nd ed (2024)

    Fulltext@MSK | Save
  • Updated efficacy and safety results from phase III GLOW study evaluating zolbetuximab plus CAPOX as first-line (1L) treatment for patients with claudin-18 isoform 2-positive (CLDN18.2+), HER2— , locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma
    Meeting Abstract

    Lordick, F.; Shah, M. A.; Shitara, K.; Ajani, J. A.; Bang, Y. J.; Enzinger, P. C.; Ilson, D. H.; van Cutsem, E.; Gallego Plazas, J.; Huang, J.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Zolbetuximab+mFOLFOX6 as first-line (1L) treatment for patients (Pts) with claudin-18.2+(CLDN18.2+) / HER2-locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: Primary results from phase 3 SPOTLIGHT study
    Meeting Abstract

    Lordick, F.; Shitara, K.; Bang, Y. J.; Enzinger, P.; Ilson, D.; Shah, M. A.; Van Cutsem, E.; Xu, R. H.; Aprile, G.; Xu, J.; more...
    Oncology Research and Treatment (2023)

    Fulltext@MSK | Save
  • Zolbetuximab + CAPOX in 1L Claudin-18.2+(CLDN18.2+)/HER2-locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: Primary phase 3 results from GLOW
    Meeting Abstract

    Lordick, F.; Xu, R. H.; Shitara, K.; Ajani, J. A.; Bang, Y. J.; Enzinger, P.; Ilson, D.; Van Cutsem, E.; Plazas, J. G.; Huang, J.; more...
    Oncology Research and Treatment (2023)

    Fulltext@MSK | Save
  • Updated efficacy and safety results from phase III GLOW study evaluating zolbetuximab + CAPOX as first-line (1L) treatment for patients with claudin-18 isoform 2-positive (CLDN18.2+), HER2–, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma
    Meeting Abstract

    Lordick, F.; Shah, M. A.; Shitara, K.; Ajani, J. A.; Bang, Y. J.; Enzinger, P. C.; Ilson, D. H.; Van Cutsem, E.; Plazas, J. G.; Huang, J.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Updated efficacy and safety results from phase III SPOTLIGHT study evaluating zolbetuximab + mFOLFOX6 as first-line (1L) treatment for patients with claudin-18 isoform 2-positive (CLDN18.2+), HER2–, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma
    Meeting Abstract

    Ajani, J. A.; Lordick, F.; Bang, Y. J.; Enzinger, P. C.; Ilson, D. H.; Shah, M. A.; Van Cutsem, E.; Xu, R. H.; Aprile, G.; Xu, J.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Prognostic value of circumferential radial margin involvement in esophagectomy for esophageal cancer: A case series
    Journal Article

    Boerner, T.; Carr, R.; Hsu, M.; Tan, K. S.; Sigel, C.; Tang, L.; Harrington, C.; Ku, G. Y.; Ilson, D. H.; Janjigian, Y. Y.; more...
    International Journal of Surgery (2023)

    Fulltext@MSK | Save